Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoadjuvant hormonal deprivation before radical prostatectomy

A M Sassine1, C C Schulman

  • 1Department of Urology, University Clinics of Brussels, Erasme Hospital, Belgium.

European Urology
|January 1, 1993
PubMed
Summary

Neoadjuvant hormone therapy significantly reduced prostate size by 40-50%, facilitating surgery and lowering blood loss. Post-treatment undetectable prostate-specific antigen (PSA) levels correlated with localized cancer, suggesting its predictive value for radical prostatectomy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erectile dysfunction and cardiovascular diseases.

Archivos espanoles de urologia·2010
Same author

To the German Society of Urology - centennial celebration.

Der Urologe. Ausg. A·2006
Same author

A simple maneuver to replace dislodged laparoscopic port.

Urology·2004
Same author

Handling and reporting of biopsy and surgical specimens of testicular cancer.

European urology·2004
Same author

[Laparoscopy in urology].

Revue medicale de Bruxelles·2003
Same author

Early prostate cancer: prevention, treatment modalities, and quality of life issues.

European urology·2003

Area of Science:

  • Urology
  • Oncology
  • Surgical Oncology

Background:

  • Radical prostatectomy is a primary treatment for localized prostate cancer.
  • Neoadjuvant therapy aims to improve surgical outcomes and disease control.
  • Complete androgen blockade involves using luteinizing hormone-releasing hormone agonists and anti-androgens like flutamide.

Purpose of the Study:

  • To evaluate the impact of neoadjuvant complete androgen blockade on prostate volume, surgical parameters, and pathological outcomes.
  • To assess the predictive value of prostate-specific antigen (PSA) response after neoadjuvant therapy for radical prostatectomy in prostate cancer patients.

Main Methods:

  • A cohort of 40 patients with prostate cancer received neoadjuvant complete androgen blockade (luteinizing hormone-releasing hormone agonist and flutamide) before radical prostatectomy.

Related Experiment Videos

  • Prostate volume, surgical blood loss, operative time, and pathological staging were assessed.
  • Post-treatment PSA levels were monitored and correlated with final pathological findings.

    • Main Results:

    • Neoadjuvant therapy reduced prostate volume by 40-50%, decreasing blood loss (avg. 400 ml) and surgery time (avg. 135 min).
    • Clinical downstaging occurred in one-third of patients, though pathological confirmation was difficult.
    • 59% of patients achieved undetectable PSA levels 3 months post-treatment; 86% of these had tumors confined to the gland (pT2). Patients with PSA > 4 ng/ml had advanced disease (pT3-pT4).

    Conclusions:

    • Neoadjuvant complete androgen blockade effectively reduces prostate volume and facilitates radical prostatectomy with improved surgical outcomes.
    • Post-neoadjuvant PSA nadir appears to be a valuable predictor of pathological tumor stage and may aid in patient selection for surgery.
    • Further large-scale randomized trials are necessary to confirm the benefits of neoadjuvant androgen deprivation on long-term oncological outcomes.